Brogden R N, Pinder R M, Sawyer P R, Speight T M, Avery G S
Drugs. 1976;12(4):249-57. doi: 10.2165/00003495-197612040-00001.
Hydrocortisone 17-butyrate is a new non-fluorinated topical corticosteroid for use in psoriasis, eczema and other inflammatory dermatoses. In double-blind paired comparisons with other topical corticosteroids, the efficacy of hydrocortisone 17-butyrate 0.1% has generally been indistinguishable from that of triamcinolone acetonide 0.1%, fluocinolone acetonide 0.025% or betamethasone 17-valerate 0.1% in patients with eczema or psoriasis. When applied to the face of patients with atrophy superimposed on rosacea and perioral dermatitis resulting from prolonged use of fluorinated topical corticosteroids, hydrocortisone 17-butyrate 0.1% did not prevent the beneficial effect of systemic tetracycline nor the disappearance of telangiectasis, and tended to be more effective than hydrocortisone 1%. This result suggests that hydrocortisone 17-butyrate may be suitable for long-term use on facial lesions, although the occurrence of moderate rebound eruption in about 10% of patients indicates the need for caution. The findings suggest that hydrocortisone 17-butyrate may be less liable to cause skin atrophy and adrenal suppression than some other potent topical corticosteroids, but trials to date have been too short to allow definite conclusions regarding possible long-term effects and have not involved infants or children.
氢化可的松17 - 丁酸酯是一种新型的非氟化外用皮质类固醇，用于治疗银屑病、湿疹和其他炎症性皮肤病。在与其他外用皮质类固醇的双盲配对比较中，0.1%的氢化可的松17 - 丁酸酯在湿疹或银屑病患者中的疗效通常与0.1%的曲安奈德、0.025%的氟轻松或0.1%的倍他米松17 - 戊酸酯相当。当将0.1%的氢化可的松17 - 丁酸酯应用于因长期使用氟化外用皮质类固醇而导致酒渣鼻和口周皮炎叠加萎缩的患者面部时，它并不能阻止全身性四环素的有益作用，也不能使毛细血管扩张消失，而且往往比1%的氢化可的松更有效。这一结果表明，氢化可的松17 - 丁酸酯可能适合长期用于面部皮损，尽管约10%的患者出现中度反跳性皮疹，这表明需要谨慎使用。研究结果表明，氢化可的松17 - 丁酸酯可能比其他一些强效外用皮质类固醇更不容易引起皮肤萎缩和肾上腺抑制，但迄今为止的试验时间太短，无法就可能的长期影响得出明确结论，而且尚未涉及婴儿或儿童。
